TY - JOUR
T1 - Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock
AU - Veres, Balazs
AU - Gallyas, Ferenc
AU - Varbiro, Gabor
AU - Berente, Zoltan
AU - Osz, Erzsebet
AU - Szekeres, Gyorgy
AU - Szabo, Csaba
AU - Sumegi, Balazs
N1 - Funding Information:
We thank Laszlo Giran, Bertalan Horvath and Helena Halasz for their excellent technical help. This work was supported by grants from Hungarian Science Foundation T34320, from the Ministry of Health and Welfare ETT 35/2000, from the Ministry of Education FKFP 0167/2001, from the Hungarian Academy of Sciences BO/00166/01 and BO/00170/01, from the University of Pecs PTE DD-KKK, from NKFP 2001 1/026 and by a Grant from the National Institutes of Health R01GM60915 to C.S.
PY - 2003/4/15
Y1 - 2003/4/15
N2 - The lack of efficacy of anti-inflammatory drugs, anti-coagulants, anti-oxidants, etc. in critically ill patients has shifted interest towards developing alternative treatments. Since inhibitors of the nuclear enzyme poly-(ADP-ribose) polymerase (PARP) were found to be beneficial in many pathophysiological conditions associated with oxidative stress and PARP-1 knock-out mice proved to be resistant to bacterial lipopolysaccharide (LPS)-induced septic shock, PARP inhibitors are candidates for such a role. In this study, the mechanism of the protective effect of a potent PARP-1 inhibitor, PJ34 was studied in LPS-induced (20mg/kg, i.p.) septic shock in mice. We demonstrated a significant inflammatory response by magnetic resonance imaging in the dorsal subcutaneous region, in the abdominal regions around the kidneys and in the inter-intestinal cavities. We have found necrotic and apoptotic histological changes as well as obstructed blood vessels in the liver and small intestine. Additionally, we have detected elevated tumor necrosis factor-α levels in the serum and nuclear factor kappa B activation in liver of LPS-treated mice. Pre-treating the animals with PJ34 (10mg/kg, i.p.), before the LPS challenge, besides rescuing the animals from LPS-induced death, attenuated all these changes presumably by activating the phosphatidylinositol 3-kinase-Akt/protein kinase B cytoprotective pathway.
AB - The lack of efficacy of anti-inflammatory drugs, anti-coagulants, anti-oxidants, etc. in critically ill patients has shifted interest towards developing alternative treatments. Since inhibitors of the nuclear enzyme poly-(ADP-ribose) polymerase (PARP) were found to be beneficial in many pathophysiological conditions associated with oxidative stress and PARP-1 knock-out mice proved to be resistant to bacterial lipopolysaccharide (LPS)-induced septic shock, PARP inhibitors are candidates for such a role. In this study, the mechanism of the protective effect of a potent PARP-1 inhibitor, PJ34 was studied in LPS-induced (20mg/kg, i.p.) septic shock in mice. We demonstrated a significant inflammatory response by magnetic resonance imaging in the dorsal subcutaneous region, in the abdominal regions around the kidneys and in the inter-intestinal cavities. We have found necrotic and apoptotic histological changes as well as obstructed blood vessels in the liver and small intestine. Additionally, we have detected elevated tumor necrosis factor-α levels in the serum and nuclear factor kappa B activation in liver of LPS-treated mice. Pre-treating the animals with PJ34 (10mg/kg, i.p.), before the LPS challenge, besides rescuing the animals from LPS-induced death, attenuated all these changes presumably by activating the phosphatidylinositol 3-kinase-Akt/protein kinase B cytoprotective pathway.
KW - Akt/protein kinase B
KW - Lipopolysaccharide
KW - MRI
KW - Poly-(ADP-ribose) polymerase
KW - Septic shock
UR - http://www.scopus.com/inward/record.url?scp=0037446371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037446371&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(03)00077-7
DO - 10.1016/S0006-2952(03)00077-7
M3 - Article
C2 - 12694878
AN - SCOPUS:0037446371
SN - 0006-2952
VL - 65
SP - 1373
EP - 1382
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 8
ER -